EU and US enhance collaboration on patient involvement in medicines development

The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have agreed to set up a forum which will share experiences and best practices for patient involvement in the development, evaluation and post-authorisation of medicines.

“Our aim as regulators is to make sure that patients have access to safe and effective medicines that improve their lives. It is important to engage to be able to fully understand their needs and priorities and make their voice heard along a medicine’s lifecycle”, explains Guido Rasi, EMA Executive Director.

The related EMA/FDA discussions currently focus on biosimilars, medicines to treat cancer, orphan medicines, medicines for children and pharmacovigilance, among other topics.

More information is available here.